Compare ABG & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABG | CRSP |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.1B |
| IPO Year | N/A | 2016 |
| Metric | ABG | CRSP |
|---|---|---|
| Price | $234.52 | $49.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 20 |
| Target Price | ★ $261.14 | $71.95 |
| AVG Volume (30 Days) | 161.9K | ★ 1.8M |
| Earning Date | 02-05-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.57 | N/A |
| EPS | ★ 28.52 | N/A |
| Revenue | ★ $17,827,000,000.00 | $38,337,000.00 |
| Revenue This Year | $6.67 | N/A |
| Revenue Next Year | $7.45 | $1,376.73 |
| P/E Ratio | $8.22 | ★ N/A |
| Revenue Growth | ★ 8.07 | N/A |
| 52 Week Low | $201.68 | $30.04 |
| 52 Week High | $312.56 | $78.48 |
| Indicator | ABG | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 38.80 |
| Support Level | $235.40 | $51.00 |
| Resistance Level | $244.89 | $56.69 |
| Average True Range (ATR) | 6.94 | 3.03 |
| MACD | -1.62 | -0.43 |
| Stochastic Oscillator | 10.47 | 1.43 |
Asbury Automotive Group is a regional collection of automobile dealerships that went public in March 2002. The company operates 152 new-vehicle stores and 37 collision centers. Over 70% of new-vehicle revenue is from luxury and import brands. Asbury also offers third-party financing and insurance products and its own F&I products via Total Care Auto. Asbury operates in 14 states (mostly Texas, the West, the Mid-Atlantic, and the Southeast). Asbury store brands include McDavid and Park Place in Texas, Koons in the Washington, D.C. area, and the Larry H. Miller brand in the Western US. Asbury generated $17.2 billion of revenue in 2024 and is based in the Atlanta area. The firm targets at least $30 billion of revenue sometime around 2030.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.